Instructions for Authors

Scope of the Pakistan Journal of Pharmaceutical Sciences

Pakistan Journal of Pharmaceutical Sciences (PJPS) is a peer-reviewed multi-disciplinary pharmaceutical and medicinal publication scheduled to appear monthly from January 2026 onwards, serving as a means for the exchange of scientific information at an international level. All manuscripts are evaluated for their scientific content and significance by the Editor-in-Chief. All submitted manuscripts should contain unpublished, original research not under consideration for publication anywhere else. Adherence to the guidelines will reduce the unnecessary delays. To avoid unnecessary delays in publication, authors are requested to strictly adhere to the guidelines.

Online Submission

Authors must ensure that their papers align with the journal's scope. Articles are comprehensive accounts of significant experimental or theoretical work. Authors are asked to write their manuscripts in a clear and concise manner and to only include the data crucial for arriving at the final conclusion. The manuscript should be submitted in MS Word 2010 and above or later format as a single file including all items, i.e., graphical abstract, abstract, figures, illustrations and tables. The chemical formula or equations should be prepared in the mathematical equations' option in MS Word, including the equation number. To facilitate a faster and more efficient peer-review and publication process, authors are strongly encouraged to submit their manuscripts through the PJPS Online Submission Portal at Online Submission Portal (Recommended): https://submission.pjps.pk/
The manuscript may be submitted to our old submission System (By File Upload) via this link https://legacy.pjps.pk/
Manuscript submission via email to submissions@pjps.pk OR pjps@uok.edu.pk.

Authors Information

All authors' names are required to be listed sequentially: First names (or initials), Middle names (or initials), and Last names (surname, family name). Each author should also include their departmental, university, or organizational affiliation with its location, such as city, state or province (if applicable), and country. It is essential that these details are accurate, as they are rarely changed after

initial submission unless under exceptional circumstances. A designated corresponding author should be identified, indicated by a superscript ("e.g., Shan"), with their email and contact information appearing on the manuscript cover page. Authors are responsible for all statements in their work and for ensuring the accuracy of bibliographic references. The editorial board reserves the right to make necessary adjustments to ensure compliance with the journal's editorial standards.

Suggested reviewers

Authors submitting a manuscript are required to suggest at least two reviewers. Detail contact information about the reviewer should be mentioned.

Structure of article

All manuscripts should be in English and prepared in A4 paper size with 1-inch (2.5 cm) margins. The text pages should be numbered consecutively. The word count for the original research article (≤8000 words), review article (≤ 12000 words), mini review (≤ 4000 words), case report (≤ 2000 words) and perspective (≤ 4000 words), excluding the abstract and bibliography. The manuscript should be organized in the following order: Title, Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgments, Authors' Contributions, Funding, Data Availability Statement, Ethical Approval, Consent to Publication, List of Abbreviations, Conflicts of Interest and References. The original manuscript should include the original inked drawings or photographs of structural formulae for direct use.

Title: Title of the manuscript should cover the aim, object and comprehensive accounts of significant experimental or theoretical work.

Authors' citation: The names of authors must be given as per their contribution, and their participation clearly must be mentioned in the Undertaking Form. Names of authors will not be increased and replaced with other names after initial submission in any stage, i.e., modification, revision and galley proof.

PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES - PJPS

Graphical Abstract

Authors are welcome to submit Graphical Abstract
Standard Size (Recommended)
It is also recommended that authors make use of the full space available.
Resolution: 600 dpi (minimum)
Preferred file formats:
TIFF (.tif)
PNG (.png)

Abstract: The abstract should be structured and include these subheadings: Background, Objectives, Methods, Results, and Conclusion. The word count of the abstract is restricted to 300 words and must provide enough detail to clearly convey the main findings and importance of the study.

Keywords: For indexing purposes, each submitted article should include three to five keywords chosen from the medical subject heading (MeSH). In addition to facilitating the indexing of articles, our keyword system assists in the assignment of qualified reviewers for your manuscript.

Abbreviations: The full form of each abbreviation should be given when first used, and then the same abbreviation should be used throughout the document. Standard abbreviations should be used without periods, and nonstandard abbreviations should be kept to a minimum.

Introduction: The introduction should give a clear and concise background of the study, explaining its context, rationale and importance. It should clearly state the problem being addressed, summarize relevant literature and identify knowledge gaps. The objective or hypotheses should be clearly presented at the end of the section. Authors should avoid including an extensive literature review or detailed results and conclusions, which are more suitable for later sections. The writing should follow a logical flow, guiding readers from the general background to the specific goal of the study.

Materials and Methods: The experimental procedures should be described in sufficient detail to enable others to repeat the experiments. Names of products/equipment and manufacturers should be included only if alternate sources are deemed unsatisfactory. Novel experimental procedures should be described in detail, but published procedures should merely be referred to by literature citation of both the original and any published modifications. The purity of key compounds and description(s) of the method(s) used to determine purity should be included in the section.

Statistical Analysis: Authors should mention the software and version used in the research article, along with the test applied for analysis.

Results: The Results section should clearly and concisely present findings, using text, tables and figures to effectively display experimental data. The same results should not be shown in more than one format (e.g., both in a table and a figure). Interpretation of results should be saved for the Discussion section. All figures and tables must be numbered in order and cited properly within the text.

Tables: The tables should be numbered sequentially with Arabic numerals and have a clear, descriptive title. Each column must have a distinct heading and units of measurement (preferably SI units) should be included. Any abbreviations or symbols used in a table must be explained in a footnote or directly below the table. Tables should be created in an editable format (e.g., .doc or .docx).

Figures and Illustrations: The figures should be clear, high-quality and submitted in TIFF or PNG format with a minimum resolution of 600 dpi. Subfigures should be labeled consistently (a), (b), (c), etc., inside the figures. Each figure must have a detailed caption below it, explaining all subfigures (e.g., Fig. 1: (a), (b), etc.) and defining any abbreviations or symbols used within the figure.

Chemical Structure: The chemical structures should be created using professional drawing software such as ChemDraw (preferred), ChemIntosh or ChemWindows. Files must be sent in TIFF or PNG format with a minimum resolution of 600 dpi. Authors should use chemical or nonproprietary names (according to USAN, INN or WHO nomenclature) when first mentioning drugs; trade or laboratory codes should be avoided unless provided as supplementary information.

Discussion: The purpose of the discussion is to interpret the results and to relate them to existing knowledge in the field in as clearly and brief as possible. Information given elsewhere in the manuscript should not be repeated in the discussion. Extensive reviews of the literature should be avoided.

Acknowledgments: This section should acknowledge financial support, technical assistance, advice from colleagues, gifts, etc. Permission must be received from the person whose contribution to the work is acknowledged in the manuscript. If there are no acknowledgments, please state "Not applicable" in this section.

Authors' Contributions: This section should clearly outline specific contributions of each author to the research and manuscript preparation according to CRediT roles like Conceptualization, Methodology, Investigation, Data Curation, Formal Analysis, Validation, Resources, Writing – Original Draft, Writing – Review and Editing, Visualization, Supervision, Project Administration and Funding Acquisition. All authors must have made substantial contributions to this work and approved the final version of the manuscript. A format example for authors' contributions is as follows:
Author 1: Conceptualization, methodology, investigation, data curation, formal analysis, validation, resources and writing – original draft; Author 2: Writing – review and editing and visualization; Author 3: Supervision, Project Administration and Funding Acquisition. All authors have read and agreed to the final published version of the manuscript.

AI Declarations

The authors must clearly disclose any use of artificial intelligence (AI) based tools or technologies during the preparation of the manuscript. This includes any use in writing assistance, data analysis, image creation, figure preparation, or editing. As per ICMJE guidelines, authors are required to disclose the use of AI in the covering letter, and acknowledgment or methods section as appropriate.

Funding

This section should list all sources of financial support for the research, including grant numbers and the names of funding agencies or sponsors. If the study did not receive any specific funding, the authors should state, "There was no funding".

Data Availability Statement

All data generated or analysed during this study are included in this published article [and its supplementary information files]. [Only use this if all data is in the manuscript or supplementary files.]
OR
The [type(s) of data] generated and/or analysed during the current study are available in the [Repository Name] repository, [PERSISTENT IDENTIFIER like DOI or Accession Number]. (e.g., [RNA-seq data] are available in the [NCBI GEO] repository under accession number.)
OR
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

Manuscripts containing data generated from animal and/or human studies must specify the committee and the institution that approved the experimental protocols used to generate these data. If ethical approval was not required for the study, the authors should state the reason or write “Not applicable” in this section.

Consent to Publication

In this section, the authors must confirm that the submitted manuscript is original, has not been published previously in any language or format, and is not currently under review elsewhere. Additionally, authors are responsible for obtaining written, informed consent for publication from anyone (or their legal guardian/next of kin) whose identifiable personal information, clinical details, or images are included in the manuscript. Authors should retain the original signed consent forms and be prepared to provide copies to the editors if requested.

List of Abbreviations

In this section, authors should provide a complete list of all abbreviations used in the manuscript along with their full forms. Abbreviations should be listed alphabetically for clarity. The authors should avoid using nonstandard or unnecessary abbreviations to maintain clarity in the text.

Chemical Names for Drugs

The chemical names for drugs should be used. If the terminology is unwieldy, nonproprietary names of drugs may be used throughout the manuscript after the first mention and identification. Formally adopted nonproprietary names listed in USAN, INN or approved by the World Health Organization, should be used. Trade names and laboratory codes should not be used except as additional information.

Conflict of Interest

Authors will include a statement about the conflict of interest. If there are no conflicts, the following statement should be included: **“The authors declare no conflict of interest.”**

Reporting guidelines

Authors must prepare manuscripts following relevant reporting guidelines for their study design to ensure clarity, transparency and reproducibility. Flow diagrams should be included, and a complete reporting checklist should be submitted as supplementary material, indicating where each item is addressed in the manuscript. All authors must strictly follow the reporting guidelines below for preparing the study for publication.

- **CONSORT**: All randomized clinical trials must include a flow diagram, and authors should provide a completed randomized trial checklist (see CONSORT Flow Diagram and Checklist; www.consort-statement.org) and a trial protocol. For further details, please visit complete guidelines at:

http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html

- **STARD and TRIPOD**: Studies of diagnostic accuracy must be reported according to STARD guidelines; (www.stard-statement.org) and TRIPOD guidelines; (www.tripod-statement.org)
- **STROBE**: Observational studies (cohort, case-control, or cross-sectional designs) must be reported according to the STROBE statement and should be submitted with their protocols; (www.strobe-statement.org).
- **CARE**: Case report must be reported according to CARE guidelines; (www.care-statement.org)
- **COREQ**: Qualitative research must be reported according to COREQ guidelines; (academic.oup.com/intqhc/article/19/6/349/1791966)
- **CHEERS**: Economic evaluations must be reported according to CHEERS guidelines; (www.bmj.com/content/346/bmj.f1049)
- **STREGA**: Genetic association studies must be reported according to STREGA guidelines; (www.medicine.uottawa.ca)
- **PRISMA**: Systematic reviews and meta-analyses must be reported according to PRISMA guidelines; (www.prisma-statement.org)
- **MOOSE**: Meta-analyses of observational studies in epidemiology must be reported according to MOOSE guidelines (http://www.ijo.in/documents/14MOOSE_SS.pdf)
- **EQUATOR**: To find the reporting guidelines see (www.equator-network.org)

Clinical trial requirements

Clinical trials must be registered in a publicly accessible registry before recruiting participants. The registration number should be included in manuscript. Only registries approved by WHO and ICMJE are acceptable. Manuscripts reporting clinical trials must include a data sharing statement within the data availability section, explaining whether data will be shared, what data will be shared, and how it can be accessed. Authors are encouraged to follow data-sharing recommendations in the ICMJE guidelines.

Registration of systematic reviews
The journal encourages the retrospective registration of systematic reviews in suitable registries (e.g., PROSPERO). Authors are advised to include registration details where applicable.

Research involving animals
Research involving animals must be conducted in accordance with international guidelines. Authors are required to submit a complete (Animal Research: Reporting of In-vivo Experiments (ARRIVE) checklist as supplementary material along with their manuscript.

Use of microorganisms
For studies involving bacteria or other microorganisms, detailed information about source, strain and relevant identification characteristics must be provided.

Use of natural products
For studies involving natural products, the source organism must be authenticated by a qualified expert. Authors should include proper documentation, including references to appropriate voucher specimens.

Use of cell lines
Studies using cell lines must include cell line name, supplier details, catalog number and passage number used in study. Additionally, authors must provide Short Tandem Repeat (STR) profiling data as supplementary material to verify cell line authenticity.

References

- References should be listed alphabetically on a separate page at the end of the manuscript. In the text, citations must follow the Harvard referencing style, using the author's surname and year of publication. When citing multiple papers by the same author in the same year, use letters (a, b, c, etc.) after the year (e.g., Smith, 2015a; Smith, 2015b).
- For single-author references, cite as (Robinson, 1998) or (Robinson, 1999; Jeong, 2000). For two authors, use (Robinson and Jeong, 2001). For more than two authors, use (Robinson et al., 2002).
- Each reference entry must include the names and initials of all authors, the full title of the article, the abbreviated title of the journal (in italics), the volume number (in bold) and the page range.

- Authors are strongly encouraged to use reference management software such as EndNote, Mendeley or Zotero to ensure accuracy and consistency in reference formatting. Download EndNote Sample File.
- The reference style and punctuation should follow the examples below:
- For journals: Yoneto K, Li SK, Higuchi WI, Jiskoot W and Herron JN (1996). Fluorescence probe studies of the interactions of 1-alkyl- 2-pyrrolidones with stratum corneum lipid liposomes. J. Pharm. Sci., 85(5): 511-517.
- For edited books: Rall TW and Schleifer LS (1985). Drugs effective in the therapy of the epilepsies. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds.), Pharmacol. Basis Ther., 7th ed., MacMillan Publishing Co., New York, pp. 446-472.
- For website: World Health Organization (2020). Coronavirus disease (COVID-19) pandemic. Available at:https://www.who.int/emergencies/diseases/novel-coronavirus-2019(Accessed 15 June 2020).

Supporting Information

Supporting information may include additional materials that complement the main text, such as experimental procedures, spectra, extended datasets, tables or supplementary figures. Authors are required to include a brief “Supporting Information Available” statement at the end of the manuscript outlining the contents. All supplementary materials should be clearly organized, numbered consecutively and submitted in appropriate digital formats. Items should be labeled as S1, S2, S3, etc., (for example, figures as Fig. S1, Fig. S2 and tables as Table S1, Table S2). Each supplementary item must be properly referenced within the main text and all figures and tables should include proper captions or legends.

Spectral Data

It may be desirable to include such data for representative compounds in a series, for novel classes of compounds, and in structural determinations. Usually, it is not desirable to include routine spectral data for every compound in the manuscript. Papers where interpretations of spectra are critical to structural elucidation and those in which band shape or fine structure needs to be illustrated may be published with spectra included. When such presentations are deemed essential, only pertinent sections should be reproduced.

Biological Data

Biological test methods must be referenced or described in sufficient detail to permit the experiments to be repeated by others. Detailed descriptions of methods should be placed in the experimental procedures section. Data may be presented as numerical expressions or in graphical form. Statistical limits (statistical significance) and statistical parameters are usually required; if these cannot be provided, the number of determinations and some indication of the variability and reliability of the results should be given, and references to the calculations should be included. Doses and concentrations should be expressed as molar quantities (e.g., mmol/kg, mM) when comparing potencies of compounds with large differences in molecular weights. The routes of administration of test compounds and vehicles used should be indicated.

Submission of Undertaking

All concerned authors are bound to submit an original, duly signed, an “Undertaking” document by them, which shows that this paper has not been submitted elsewhere and is not plagiarized, in according ICMJE and COPE Guidelines. All contributors are also required to mention their names and affiliations. Additionally, all correspondence will be conducted exclusively with the corresponding author at the provided email address only. The author(s) information given in the “Undertaking” document must be same as submitted with the manuscript.

Proofs

Proofs are sent to the corresponding author of the manuscripts through email or online web portal. Proof should be verified against the manuscript and appropriate corrections made. Substantial changes in a manuscript after composing have been made require editorial approval and, in some cases, may be the cause for re-reviewing.

Articles in Press

Articles in-press and journal proofs provide early access to research before its formal publication.

Key Characteristics

• Status: Peer-reviewed, revised, and officially accepted for publication.
• Visibility: Published online early to ensure immediate access for the research community.
• Completeness: Lacks final bibliographic details like volume, issue and page numbers.
• Citation: Can be cited immediately using the author(s) names, title, online publication year and DOI.
• Finalization: Replaced entirely by the final version once assigned to a specific issue.
• Risk Factor: Text may still contain minor errors that will be corrected before final release.
• Legal Terms: All standard journal disclaimers and legal terms apply to the early version.

Proofreading and Deadlines

• Timeline: Authors must submit all final corrections within a two-week window.
• Finality: No further edits or corrections are permitted after this deadline passes.
• Consequences: Missing the deadline allows the publisher to finalize the text with Editor-in-Chief (EIC) approval.
• Delays: Late responses may cause the article to be postponed to a future issue.
• Removal: Failing to return proofs can result in the article being completely unpublished.

Status of Uncorrected Proofs
• Modification: The editorial board retains the right to alter the text partially or totally.
• Rejection: Articles can still be rejected during this subsequent production stage.
• Status: These documents do not represent a "finally published" scientific work.

Article Publication Charges (APC)

The PJPS publishes articles through either a fast publication system (FPS/UFR) or a regular publication system (RPS). To ensure quick publication of research articles, PJPS can arrange urgent publication via:

- The Fast Publication System (FPS), with charges of Rs. 15,000 (local) or US$200.00 (international) per page.
- An Ultra-Fast Review (UFR) is also available for international submissions, with charges of US$ 200 per page plus an additional US$1,000-1,500 per article.
- The publication fee for the Regular Publication System (RPS) is Rs. 3000 (local) or US$ 75.00 (international) per page.

Payment Details

Payments can be made through online banking within a month for RPS and within a week for FPS/UFR.
Account Title: Pakistan Journal of Pharmaceutical Sciences
Bank: United Bank Limited, University Campus Branch, University of Karachi
Account Number: 1146-010-1731-3 and Swift Code: UNILPKKA
IBAN: PK10 UNIL 0112 1146 010173 13

APC Discounts and Waivers

The PJPS offers APC discounts to corresponding authors based in countries classified by the World Bank as low-income economies. Requests for a discount must be submitted at the time of manuscript

submission, as applications received after submission may not be considered.

To support the request, authors should provide:

- Complete institutional affiliation of all authors.
- Information on the institution(s) where the research was conducted.
- Details of all funding sources, including research grants and financial support received for the study

All discount requests are evaluated on a case-by-case basis, and eligibility is determined according to the journal's policies and the information provided by the authors.

Publication Timeline

- **Submission to First Decision**: 4 days
- **From First Decision to Decision After Reviewing**:
  Ultra-fast Review (UFR): 7 to 10 days
  Fast Publication System (FPS): 14 to 28 days
  Regular Publication System (RPS): 30 to 60 days
- **Submission of Revised Manuscript to Final Decision**: 1 to 3 days

Acceptance to Online Publication

- **Acceptance to Online Publication**:
  Ultra-fast Review (UFR): 1–2 months
  Fast Publication System (FPS): 2 to 4 months
  Regular Publication System (RPS): 4 to 6 months
- **Acceptance Rate**: 15%

How to Order

To obtain a printed copy of the journal issue, the order should be emailed to the following email addresses or sent to the Office of the Editor-in-Chief, PJPS, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi-75270, Pakistan. The cost is Rs.5000 (local) and US$250 (international) per copy (including shipping and handling). Additionally, the journal offers a subscription for its

printed version with an annual fee of Rs.25,000 (local) and US$1250 (international).